EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Bhavesh Shah, Rickard Sandin, Yun Liu iD, Laura R Bobolts, Yannan Hu, Isha Mol iD, Alexander Schepart, David M Hughes, Jim Hart, Patrick Hlavacek

ClinicoEconomics and Outcomes Research · 2025-04 · Volume 17 · 289-302

DOI: 10.2147/ceor.s501404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ClinicoEconomics and Outcomes Research, 2025-04. Verfasst von Bhavesh Shah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Boston Medical Center, Boston, MA, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

US commercial payerbudget impact modelcost of caremedicaremultiple myelomatriple-class exposedtriple-class refractory

Autor:innen und Institutionen

  • Boston Medical Center, Boston, MA, USA.
  • Pfizer AB, Stockholm, Sweden.
  • Cytel, Rotterdam, Netherlands.
  • Oncohealth, Pompano Beach, FL, USA.
  • Pfizer Inc, New York, NY, USA.

ORCID-Profile: Yun Liu, Isha Mol

Zitieren

APA

Shah, B., Sandin, R., Liu, Y., Bobolts, L. R., Hu, Y., Mol, I., Schepart, A., Hughes, D. M., Hart, J., & Hlavacek, P. (2025). Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. ClinicoEconomics and Outcomes Research, Volume 17, 289-302. https://doi.org/10.2147/ceor.s501404

Vancouver

Shah B, Sandin R, Liu Y, Bobolts LR, Hu Y, Mol I, et al. Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma. ClinicoEconomics and Outcomes Research. 2025;Volume 17:289-302. doi:10.2147/ceor.s501404

BibTeX
@article{Shah2025,
  author = {Shah, Bhavesh and Sandin, Rickard and Liu, Yun and Bobolts, Laura R and Hu, Yannan and Mol, Isha and Schepart, Alexander and Hughes, David M and Hart, Jim and Hlavacek, Patrick},
  title = {Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma},
  journal = {ClinicoEconomics and Outcomes Research},
  year = {2025},
  volume = {Volume 17},
  pages = {289--302},
  doi = {10.2147/ceor.s501404}
}
Kostenlos starten →